Clinical Trial

VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

Study acronym: V-INCLUSION
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
VictORION-INCLUSION (V-INCLUSION) seeks to evaluate the effectiveness of inclisiran as an innovative therapy with the potential to help bridge care gaps in historically understudied and undertreated populations by leveraging electronic health records (EHR) in multiple US Healthcare Systems (HCS) to systematically identify those at high risk for and already diagnosed with ASCVD for more expeditious achievement of LDL-C targets.
Protocol Amendment History 1 change
notable Primary completion pushed: 2026-12 -> 2026-12-31 2026-07-30
Trial Details
NCT Number NCT06249165
Lead Sponsor Duke University
Collaborators: Novartis Pharmaceuticals
Conditions Atherosclerotic Cardiovascular Disease
Enrollment 130 participants
Start Date 2024-12-16
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-29